BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35901328)

  • 21. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic variability in L1 and L2 genes of HPV-16 and HPV-58 in Southwest China.
    Yue Y; Yang H; Wu K; Yang L; Chen J; Huang X; Pan Y; Ruan Y; Zhao Y; Shi X; Sun Q; Li Q
    PLoS One; 2013; 8(1):e55204. PubMed ID: 23372836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
    Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
    Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
    Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
    J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
    [No Abstract]   [Full Text] [Related]  

  • 26. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.
    Gersch ED; Gissmann L; Garcea RL
    Antivir Ther; 2012; 17(3):425-34. PubMed ID: 22293302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
    Karanam B; Jagu S; Huh WK; Roden RB
    Immunol Cell Biol; 2009; 87(4):287-99. PubMed ID: 19421199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designing of multi-epitope chimeric vaccine using immunoinformatic platform by targeting oncogenic strain HPV 16 and 18 against cervical cancer.
    Kumar A; Sahu U; Kumari P; Dixit A; Khare P
    Sci Rep; 2022 Jun; 12(1):9521. PubMed ID: 35681036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
    Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
    Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
    Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
    Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
    J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
    Yadav R; Zhai L; Tumban E
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16.
    Chen J; Wang D; Wang Z; Wu K; Wei S; Chi X; Qian C; Xu Y; Zhou L; Li Y; Zhang S; Li T; Kong Z; Wang Y; Zheng Q; Yu H; Zhao Q; Zhang J; Xia N; Li S; Gu Y
    J Virol; 2023 Mar; 97(3):e0181922. PubMed ID: 36815785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.
    Xu YF; Wang QY; Zhang HT; Han YH; Song GX; Xu XM
    Chin Med J (Engl); 2007 Mar; 120(6):503-8. PubMed ID: 17439745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variability of human papillomavirus type 66 L1 gene among women presenting for cervical cancer screening in Chile.
    Balanda M; Fernández J; Vergara N; Campano C; Arata L; Martín HS; Ramírez E
    Med Microbiol Immunol; 2019 Dec; 208(6):757-771. PubMed ID: 31165237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
    Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
    Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.